Body Composition

Body composition is the highest-traffic goal in the peptide community and the one where evidence quality varies most across the stack you actually end up running. The FDA-approved GLP-1/GIP drugs (semaglutide, tirzepatide) have Tier 1 evidence for weight loss — the SURPASS and SURMOUNT trials are real, large, replicated. Everything users layer on top of that (GH-axis peptides for "lean mass sparing," AOD-9604 for "targeted lipolysis") is community practice with much weaker evidence.

This protocol sequences honestly: start where the evidence is strongest (the GLP-1/GIP foundation), only layer the more speculative pieces once you've validated the foundation works for you, and have an explicit taper or maintenance plan from day one. Body composition work without an exit plan tends to result in rebound — particularly for the muscle-mass losses from caloric restriction.

If you have type 2 diabetes, established cardiovascular disease, or a meaningful surgical-weight-loss alternative on the table, this protocol is the wrong starting point — talk to your physician about what's actually appropriate. This is for healthy adults pursuing cosmetic or longevity-adjacent body-composition goals.

Phases

1. Phase 1 — Metabolic foundation (tirzepatide titration)

   weeks 1-12

   Standard tirzepatide titration: 2.5mg weekly for weeks 1-4, then 5mg weekly for weeks 5-8, then 7.5mg weekly for weeks 9-12. Most users find an effective maintenance dose between 5-10mg; do not exceed 15mg/week. Slow titration is load-bearing for GI tolerance — escalating faster than every 4 weeks produces the GI side-effects most people quit the medication over.

   • Tirzepatide2.50 mg · weekly · evening

     Start 2.5mg SubQ once weekly. Evening dosing puts the worst GI side-effects through sleep. Titrate every 4 weeks based on tolerance + scale response.

   What “working” looks like

   Reduced appetite + early satiety by week 2. Weight loss of ~1-2 lb/week emerging at the 5mg dose. Fewer food-noise distractions. Stable energy at consistent caloric intake.

   Decision criteria

   If working at week 8 (5mg dose): hold at this dose through week 12 to confirm tolerability, then consider Phase 2. If not working at week 8: titrate to 7.5mg per the standard ramp. If GI side-effects intolerable: hold at last-tolerated dose; do not advance. If no scale response at 10mg by week 12: consider whether GLP-1s are the right tool for your physiology — some users are non-responders.

   Labs to pull

   • HbA1c (baseline glycemic control)
   • Fasting glucose + insulin → calculate HOMA-IR
   • Lipid panel including ApoB
   • Lipase + amylase (rule out pre-existing pancreatic inflammation)
   • ALT + AST + CMP (baseline liver + kidney)

2. Phase 2 — GH-axis layer for lean-mass sparing (CJC/Ipa)

   weeks 12-26

   Add the CJC-1295 + Ipamorelin blend at bedtime to support lean-mass retention during caloric deficit. Mechanism: GHRH analog (CJC) + GHRP (Ipa) co-stimulate endogenous GH pulse → IGF-1 → anabolic signaling that opposes the catabolic state of sustained caloric restriction. This is Tier 3 community practice; no RCT validates the GLP-1 + GH-axis co-administration pattern. Mechanistically coherent, evidence-thin.

   • Tirzepatide5 mg · weekly · evening

     Continue Phase 1 maintenance dose (whatever you tolerated at — most users land at 5-10mg). Do not modify dose just because Phase 2 starts.

   • CJC-1295 / Ipamorelin100 mcg · daily · evening

     100mcg of each peptide SubQ at bedtime, fasted (no food within 2 hours). Bedtime aligns with natural GH pulse. Do not co-inject with tirzepatide — separate injection sites + ideally separate days when both are due.

   What “working” looks like

   Stable or improving DEXA lean mass despite continued fat-mass loss. Better recovery between training sessions. Sleep quality often improves. Energy stays high despite the caloric deficit.

   Decision criteria

   If working at week 20: continue through week 26 then move to Phase 3 maintenance. If insulin sensitivity has worsened (HOMA-IR up vs baseline): pause CJC/Ipa, repeat labs in 4 weeks — GH-axis stimulation can blunt insulin sensitivity, which works against the GLP-1 mechanism. If no DEXA lean-mass benefit by week 24 despite consistent dosing: discontinue Phase 2 — the GH-axis layer isn't working in your physiology.

   Labs to pull

   • Repeat HbA1c + fasting glucose + insulin (compare to Phase 1 baseline)
   • IGF-1 (after 4-6 weeks on CJC/Ipa — flag if above normal range for age)
   • DEXA scan if available (gold standard for lean vs fat-mass tracking)

3. Phase 3 — Maintenance + optional taper

   weeks 26+

   Maintenance plan is required from day one of this protocol; rebounding off GLP-1s without a plan tends to recover the lost weight and worsen lean-mass-to-fat-mass ratio vs the starting point. Two paths: (A) maintain Phase 2 indefinitely at the lowest effective tirzepatide dose; or (B) taper tirzepatide over 8-12 weeks while keeping GH-axis support for body-composition recomposition. Path B is harder but matches the editorial intent of "use the foundation to lose, use the layers to maintain."

   • Tirzepatide2.50 mg · weekly · evening

     Taper path: drop dose one step every 2-4 weeks (10 → 7.5 → 5 → 2.5 → off). Maintenance path: stay at lowest effective dose indefinitely. Either is editorially valid; choose with your clinician based on your maintenance plan.

   • CJC-1295 / Ipamorelin100 mcg · daily · evening

     Continue maintenance dosing. Cycle 5 days on / 2 days off if you want to reduce IGF-1 exposure — community practice; no strong evidence either schedule is superior.

   • AOD-9604300 mcg · daily · evening

     OPTIONAL. 300mcg SubQ at bedtime if you want to layer a low-cost targeted-lipolysis peptide during the taper. Evidence base is thin; cost is low; risk is also low.

   What “working” looks like

   Sustained weight + body composition 3+ months past Phase 1 nadir. Stable energy + appetite at the new bodyweight. Training capacity preserved.

   Decision criteria

   If sustaining weight at 3 months past Phase 1 end: protocol is succeeding; continue indefinitely. If rebound (>5% bodyweight gain): you tapered tirzepatide too fast or your maintenance plan needs a real audit (sleep, training, caloric intake). Returning to a higher tirzepatide dose works but is editorially a flag that the underlying lifestyle changes haven't taken root. AOD-9604 should be discontinued if it's not adding visible benefit — keep the stack lean.

Often combined with

• Longevity

  REAL TENSION. The Longevity protocol uses rapamycin (mTOR inhibitor — anti-anabolic, pro-autophagy) which works directly against the Phase 2 GH-axis layer of Body Composition (CJC + Ipa stimulating IGF-1 — pro-anabolic, pro-mTOR). The two protocols pull the central mTOR axis in opposite directions. There is no clean answer: pick one direction at a time and stick with it, or cycle deliberately between phases. Discuss with your clinician explicitly.

• Energy & Vitality

  Sustained caloric deficit often produces fatigue and B-vitamin depletion. The cofactor restoration in Energy Phase 1 is a clean pairing — supports the metabolic demands of Phase 1 of Body Composition without any peptide interaction conflicts.

• Recovery from Injury

  If recovering from injury concurrent with body-composition work, both protocols sequence GH-axis support. Layer carefully — IGF-1 stimulation from CJC/Ipa in one protocol counts toward the other; do not double-dose. Pick whichever protocol's Phase 2 came first and treat it as primary.